Abstract
Purpose of Review: There is ample evidence of the benefits and safety of low-density lipoprotein (LDL)-lowering therapies in the prevention of atherosclerotic cardiovascular disease. While statins remain the first-line agent for LDL reduction, several new therapies are now available. This narrative review provides an overview of currently available non-statin LDL-lowering agents, specifically mechanisms of action and data on efficacy and safety. It also discusses recommendations on their use in clinical practice. Recent Findings: Ezetimibe, PCSK9 inhibitors, and bempedoic acid have proven safe and efficacious in reducing cardiovascular events in large randomized controlled trials. Inclisiran is a promising agent that suppresses PCSK9 mRNA translation and is currently under investigation in a large clinical outcomes randomized controlled trial assessing its effect on clinical outcomes. Summary: Expert consensus advocates for lower LDL targets in higher risk patients and escalation to or a combination of non-statin therapies as needed to achieve these goals.
Original language | English (US) |
---|---|
Pages (from-to) | 221-231 |
Number of pages | 11 |
Journal | Current Cardiology Reports |
Volume | 26 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2024 |
Keywords
- Bempedoic acid
- Ezetimibe
- Hyperlipidemia
- Inclisiran
- Low-density lipoprotein
- Proprotein convertase subtilisin/kexin type 9 inhibitor
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine